Aldeyra Therapeutics (ALDX) Reports Q3 Loss of $0.52

Aldeyra Therapeutics (NASDAQ: ALDX) reported Q3 EPS of ($0.52), versus ($0.32) reported last year.

"The third quarter was highlighted by positive results from our Phase 2b clinical trial of reproxalap in dry eye disease and an investigator-sponsored Phase 1/2 clinical trial of ADX-1612 in malignant mesothelioma," commented Todd C. Brady, M.D., Ph.D. "In addition, we completed a successful financing to support a broad and diversified clinical development plan that includes Phase 3 clinical trials in dry eye disease, noninfectious anterior uveitis, allergic conjunctivitis, and Sjögren-Larsson Syndrome. We look forward to the announcement of our next major milestone, results from the ALLEVIATE Phase 3 clinical trial in allergic conjunctivitis, in early 2019."

For earnings history and earnings-related data on Aldeyra Therapeutics (ALDX) click here.

You May Also Be Interested In

• Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
• Evercore ISI Upgrades Owens Corning (OC) to Outperform
• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations